| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00109-013-1034-0 |
| P698 | PubMed publication ID | 23636507 |
| P50 | author | Elena Kaschina | Q65659373 |
| Christa Thöne-Reineke | Q88776003 | ||
| Johannes Baulmann | Q92126467 | ||
| Svetlana Slavic | Q114782167 | ||
| Dilyara Lauer | Q114782168 | ||
| Manuela Sommerfeld | Q114782169 | ||
| Ulrich Rudolf Kemnitz | Q114782170 | ||
| Aleksandra Grzesiak | Q114782171 | ||
| Kai Kappert | Q114782172 | ||
| Ulrich Kintscher | Q56956502 | ||
| Ludovit Paulis | Q56958453 | ||
| Thomas Unger | Q65602952 | ||
| P2093 | author name string | Manuela Trappiel | |
| P2860 | cites work | Endothelial Control of Arterial Distensibility Is Impaired in Chronic Heart Failure | Q71807619 |
| A simple method for preparation of cultured cardiac fibroblasts from adult human ventricular tissue | Q73647897 | ||
| Aortic stiffness correlates with an increased extracellular matrix turnover in patients with dilated cardiomyopathy | Q79849789 | ||
| CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis | Q83820609 | ||
| Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations | Q24309438 | ||
| Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity | Q24648835 | ||
| Structure of a cannabinoid receptor and functional expression of the cloned cDNA | Q28240076 | ||
| Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide | Q28349586 | ||
| CB1 cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction | Q30918735 | ||
| Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle | Q31136248 | ||
| Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity | Q34028741 | ||
| SR141716A, a potent and selective antagonist of the brain cannabinoid receptor | Q34332716 | ||
| Cellular mechanisms of ischemia-reperfusion injury | Q35073954 | ||
| The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis | Q35169067 | ||
| The endocannabinoid system: a general view and latest additions | Q35639524 | ||
| Endocannabinoids and the control of energy balance | Q36671574 | ||
| Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations | Q36940347 | ||
| Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function | Q36967674 | ||
| Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. | Q37019662 | ||
| Transforming growth factor (TGF)-β signaling in cardiac remodeling. | Q37808014 | ||
| Novel therapeutic targets for the treatment of heart failure. | Q37893956 | ||
| Functional CB1 cannabinoid receptors in human vascular endothelial cells | Q38314869 | ||
| Endocannabinoids are implicated in the infarct size-reducing effect conferred by heat stress preconditioning in isolated rat hearts | Q40577402 | ||
| Myocardial infarct size and ventricular function in rats | Q41488928 | ||
| Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. | Q42003359 | ||
| Cleaved high molecular weight kininogen, a novel factor in the regulation of matrix metalloproteinases in vascular smooth muscle cells | Q42458466 | ||
| CB1 receptor inhibition leads to decreased vascular AT1 receptor expression, inhibition of oxidative stress and improved endothelial function | Q42469710 | ||
| Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. | Q42553964 | ||
| Substantially altered expression pattern of cannabinoid receptor 2 and activated endocannabinoid system in patients with severe heart failure | Q43237260 | ||
| Endogenous cannabinoids mediate hypotension after experimental myocardial infarction | Q43818881 | ||
| The cannabinoid CB1 receptor antagonist, rimonabant, protects against acute myocardial infarction. | Q46001116 | ||
| Differential CB1 and CB2 cannabinoid receptor-inotropic response of rat isolated atria: endogenous signal transduction pathways | Q46483537 | ||
| Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia | Q46807918 | ||
| Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. | Q48191169 | ||
| The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy. | Q51796834 | ||
| Direct angiotensin II type 2 receptor stimulation in Nω-nitro-L-arginine-methyl ester-induced hypertension: the effect on pulse wave velocity and aortic remodeling. | Q52890458 | ||
| Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? | Q54506199 | ||
| P433 | issue | 7 | |
| P921 | main subject | myocardial infarction | Q12152 |
| metabolic syndrome | Q657193 | ||
| cannabinoid receptor | Q421237 | ||
| cannabinoids | Q422936 | ||
| CNR2 | Q17907844 | ||
| P304 | page(s) | 811-823 | |
| P577 | publication date | 2013-05-01 | |
| P1433 | published in | Journal of Molecular Medicine | Q6295593 |
| P1476 | title | Cannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome | |
| P478 | volume | 91 |
| Q34582334 | Acute and chronic systemic CB1 cannabinoid receptor blockade improves blood pressure regulation and metabolic profile in hypertensive (mRen2)27 rats |
| Q33579016 | Cannabinoid CB1 receptor overactivity contributes to the pathogenesis of idiopathic pulmonary fibrosis |
| Q53587541 | Cannabinoid receptor 1 is a major mediator of renal fibrosis. |
| Q28395270 | Cannabis exposure as an interactive cardiovascular risk factor and accelerant of organismal ageing: a longitudinal study |
| Q47804552 | Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly |
| Q48238653 | Chronic inhibition of fatty acid amide hydrolase by URB597 produces differential effects on cardiac performance in normotensive and hypertensive rats. |
| Q57024731 | Comparative evaluation of cannabinoid receptors, apelin and S100A6 protein in the heart of women of different age groups |
| Q92152415 | Endocannabinoid System in the Airways |
| Q35572176 | Endocannabinoid signaling at the periphery: 50 years after THC. |
| Q38593133 | Endocannabinoids and the Cardiovascular System in Health and Disease |
| Q38268870 | Intramyocardial haemorrhage after acute myocardial infarction |
| Q37139613 | MMP-9 signaling in the left ventricle following myocardial infarction |
| Q53437025 | Possible mechanism by which renal sympathetic denervation improves left ventricular remodelling after myocardial infarction. |
| Q36548944 | Protection from Radiation-Induced Pulmonary Fibrosis by Peripheral Targeting of Cannabinoid Receptor-1. |
| Q43857237 | Rehabilitating rimonabant |
| Q64889523 | Role of Cannabinoid Receptor Type 1 in Insulin Resistance and Its Biological Implications. |
| Q37085532 | Role of the endocannabinoid system in diabetes and diabetic complications |
| Q59326934 | Sex differences in distribution of cannabinoid receptors (CB1 and CB2), S100A6 and CacyBP/SIP in human ageing hearts |
| Q37327465 | The CB1 receptor mediates the peripheral effects of ghrelin on AMPK activity but not on growth hormone release |
| Q46204521 | The endocannabinoid system in cardiovascular function: novel insights and clinical implications |
Search more.